0001209191-21-051910.txt : 20210817
0001209191-21-051910.hdr.sgml : 20210817
20210817170033
ACCESSION NUMBER: 0001209191-21-051910
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210816
FILED AS OF DATE: 20210817
DATE AS OF CHANGE: 20210817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Akinsanya Karen
CENTRAL INDEX KEY: 0001797672
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39206
FILM NUMBER: 211183550
MAIL ADDRESS:
STREET 1: SCHRODINGER, INC.
STREET 2: 120 WEST 45TH STREET, 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Schrodinger, Inc.
CENTRAL INDEX KEY: 0001490978
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 954284541
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 503-299-1150
MAIL ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-16
0
0001490978
Schrodinger, Inc.
SDGR
0001797672
Akinsanya Karen
C/O SCHRODINGER, INC.,
120 WEST 45TH STREET, 17TH FLOOR
NEW YORK
NY
10036
0
1
0
0
See Remarks
Common Stock
2021-08-16
4
M
0
20181
17.00
A
20181
D
Common Stock
2021-08-16
4
M
0
4180
4.34
A
24361
D
Common Stock
2021-08-16
4
M
0
13377
3.22
A
37738
D
Common Stock
2021-08-16
4
S
0
21691
57.4334
D
16047
D
Common Stock
2021-08-16
4
S
0
16047
58.1745
D
0
D
Stock Option (right to buy)
17.00
2021-08-16
4
M
0
20181
0.00
D
2030-02-05
Common Stock
20181
180478
D
Stock Option (right to buy)
4.34
2021-08-16
4
M
0
4180
0.00
D
2028-11-29
Common Stock
4180
45985
D
Stock Option (right to buy)
3.22
2021-08-16
4
M
0
13377
0.00
D
2028-08-03
Common Stock
13377
13378
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.90 to $57.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.905 to $58.86, inclusive.
This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024.
This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.
The option was granted on August 3, 2018. The shares underlying the option are scheduled to vest in equal yearly installments from May 14, 2018 through May 14, 2022.
EVP, Chief Biomedical Scientist, Head of Discovery R&D
/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
2021-08-17